About this trial
Autism Spectrum Disorders (ASD), affect approximately 1% of the general population and are characterized by impairments in social communication associated with repetitive/stereotyped behaviors. Approximately one-third of these patients display gastrointestinal (GI) symptoms, and a growing number of studies suggest abnormalities of gut microbiota in ASD. Gut microbiota and the brain interact through complex pathways. Preliminary evidence in adults with ASD suggests that modulation of the gut microbiota by probiotics and/or prebiotics and more recently by fecal microbiota transplantation could improve GI symptoms but also socio-communication deficit, with persistent improvement at year 2.
Eligibility criteria
Qualifiers
ASD diagnosis based on DSM-5 criteria
Gastrointestinal symptoms: at least a score of 5 on 1 of the 5 GSRS domains (diarrhea, abdominal pain, constipation, indigestion, reflux) for over a period of 1 year or more
Age between 36 and 72 months
Consent from all legal guardians
Disqualifiers
Severe intellectual deficit (IQ<30) or another uncontrolled comorbidity (e.g. epilepsy)
Recent change in ASD global care (cognitive behavioral therapy 6 weeks before inclusion)
Actual or past psychotropic medication
Contraindications to colon preparation (Picoprep®) and/or to Meopa)
Trial design
Treatments tested in this trial
- FMT Protocol
Treatment groups
Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Fondation initiative autisme
Collaborator
Fondation Erie
Collaborator
Biocodex microbiota fondation
Collaborator